Previous reports demonstrated that bortezomib (Velcade, formerly known as PS-341), a potent and selective proteasome inhibitor approved by the FDA for the treatment of patients with multiple myeloma, is able to block chemotherapy-induced NF-κB activation and augment the apoptotic response to chemotherapeutic agents [22]. Here, NFKB1 is linked to AL amyloidosis.